Literature DB >> 28686156

High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.

Andrea Messori1, Flora Peyvandi2,3,4, Sabrina Trippoli1, Roberta Palla4, Frits R Rosendaal5, Pier Mannuccio Mannucci2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28686156      PMCID： PMC5839620          DOI： 10.2450/2017.0352-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  8 in total

1.  Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.

Authors:  Lusine Abrahamyan; Andrew R Willan; Joseph Beyene; Marjorie Mclimont; Victor Blanchette; Brian M Feldman
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

2.  Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies.

Authors:  Matteo Nicola Dario Di Minno; Emanuela Marchesini; Lelia Valdrè
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

3.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Value Health       Date:  2013 Mar-Apr       Impact factor: 5.725

Review 4.  How we choose factor VIII to treat hemophilia.

Authors:  Pier Mannuccio Mannucci; Maria Elisa Mancuso; Elena Santagostino
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

5.  Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.

Authors:  A B Colowick; R L Bohn; J Avorn; B M Ewenstein
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

Review 6.  Purchasing factor concentrates in the 21st century through competitive tendering.

Authors:  C R M Hay
Journal:  Haemophilia       Date:  2013-05-28       Impact factor: 4.287

7.  Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.

Authors:  Alessandro Gringeri; Lorenzo G Mantovani; Luciana Scalone; Pier Mannuccio Mannucci
Journal:  Blood       Date:  2003-06-19       Impact factor: 22.113

8.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

Authors:  Flora Peyvandi; Pier M Mannucci; Isabella Garagiola; Amal El-Beshlawy; Mohsen Elalfy; Vijay Ramanan; Peyman Eshghi; Suresh Hanagavadi; Ramabadran Varadarajan; Mehran Karimi; Mamta V Manglani; Cecil Ross; Guy Young; Tulika Seth; Shashikant Apte; Dinesh M Nayak; Elena Santagostino; Maria Elisa Mancuso; Adriana C Sandoval Gonzalez; Johnny N Mahlangu; Santiago Bonanad Boix; Monica Cerqueira; Nadia P Ewing; Christoph Male; Tarek Owaidah; Veronica Soto Arellano; Nathan L Kobrinsky; Suvankar Majumdar; Rosario Perez Garrido; Anupam Sachdeva; Mindy Simpson; Mathew Thomas; Ezio Zanon; Bulent Antmen; Kaan Kavakli; Marilyn J Manco-Johnson; Monica Martinez; Esperanza Marzouka; Maria G Mazzucconi; Daniela Neme; Angeles Palomo Bravo; Rogelio Paredes Aguilera; Alessandra Prezotti; Klaus Schmitt; Brian M Wicklund; Bulent Zulfikar; Frits R Rosendaal
Journal:  N Engl J Med       Date:  2016-05-26       Impact factor: 91.245
  8 in total
  4 in total

1.  Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.

Authors:  Albert Farrugia; Megha Bansal
Journal:  Blood Transfus       Date:  2017-10-03       Impact factor: 3.443

2.  Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".

Authors:  Andrea Messori; Flora Peyvandi; Sabrina Trippoli; Roberta Palla; Frits R Rosendaal; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2017-12-22       Impact factor: 3.443

3.  Emicizumab for the treatment of haemophilia A: a narrative review.

Authors:  Massimo Franchini; Giuseppe Marano; Ilaria Pati; Fabio Candura; Samantha Profili; Eva Veropalumbo; Francesca Masiello; Liviana Catalano; Vanessa Piccinini; Stefania Vaglio; Simonetta Pupella; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-05       Impact factor: 3.443

Review 4.  Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.

Authors:  Albert Farrugia; Giancarlo M Liumbruno; Fabio Candura; Samantha Profili; Josephine Cassar
Journal:  Blood Transfus       Date:  2018-09-03       Impact factor: 3.443
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.